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Safety and Efficacy of Combining Sunitinib with
Bevacizumab  Paclitaxel/Carboplatin in Non-small Cell
Lung Cancer
Mark A. Socinski, MD,* Frank A. Scappaticci, MD, PhD,† Meghna Samant, PhD,†
Margaret M. Kolb, DrPH,† and Mark F. Kozloff, MD‡§
Introduction: Bevacizumab (B) improves survival of patients with
metastatic, nonsquamous non-small cell lung cancer. Based on encour-
aging results from preclinical studies combining B with sunitinib (S), a
phase II, randomized, open-label study (Study Assessing the Blockade
of both VEGF Receptor and ligand to enhance Efficacy in Lung) was
initiated to assess clinical outcomes of adding S to paclitaxel
(P)/carboplatin (C)  B (PCB) for first-line treatment of locally
advanced, metastatic, or recurrent nonsquamous non-small cell lung
cancer.
Methods: Study enrollment was to occur in three phases. In the first
phase, patients received PC  B (15 mg/kg every 3 weeks), S
(25 mg daily, 2 weeks on, 1 week off). If tolerated, the second phase
would include a third cohort receiving 37.5 mg S. The third phase
would consist of PCB  highest tolerable dose S.
Results: Between March 2007 and January 2008, 26 patients were
randomized to receive PCB and 30 to PCB  S 25 mg. Because of
poor tolerability, none of the patients were escalated to 37.5 mg S.
Median treatment duration was 10.3 weeks for PCB and 6.0 weeks
for PCB  S. Thirty-five percent of patients on PCB  S required
S dose reduction, 52% required S treatment interruption, and 59%
discontinued S because of adverse events, most frequently hemato-
logic events (neutropenia, thrombocytopenia, and leukopenia) and
fatigue. Patients receiving PCB  S required more B interruptions
(38% versus 19% for PCB) and discontinuation (52% versus 35%)
because of adverse events. Survival data were limited by small
sample sizes and limited treatment duration. Overall survival was
not mature at time of analysis: median 6.6 months for PCB  S and
not reached for PCB. Two out of 25 efficacy-evaluable patients
randomized to the PCB  S cohort had confirmed partial responses,
compared with 5 of 19 randomized to the PCB cohort.
Conclusions: The addition of S to PCB was not well tolerated
because of toxicities. This combination should not be studied further
at these doses and schedules.
Key Words: Non-small cell lung cancer, Bevacizumab, Sunitinib,
Metastatic disease, Nonsquamous, Metastatic, Locally advanced,
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It is estimated that 215,020 cases of lung cancer were newlydiagnosed in 2008 and that more than 160,000 men and
women died of the disease.1 Non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers.2
The recombinant, humanized monoclonal antibody bevaci-
zumab (B, Avastin; Genentech, South San Francisco, CA) is
directed against vascular endothelial growth factor (VEGF),
an essential endothelial cell mitogen and survival factor.3–7 B
in combination with paclitaxel (P) and carboplatin (C) (PCB)
is Food and Drug Administration approved for first-line
treatment of patients with unresectable, locally advanced,
recurrent or metastatic nonsquamous NSCLC,4–7 based on
results from the phase III trial E4599 in which PCB treatment
provided survival benefit over treatment with PC alone.4
Additional improvements to NSCLC therapy are being
sought beyond the improvement offered by PCB therapy.
One approach involves combination of PCB with a multitar-
geted agent possessing broad inhibitory effects on pathways
involved in angiogenesis, including VEGF receptor (VEGFR)-
mediated pathways and other receptor tyrosine kinase-(RTK)
mediated pathways known to be important in NSCLC.8,9
Sunitinib (S) is a small molecule oral inhibitor of
multiple RTKs, including platelet-derived growth factor re-
ceptors (PDGFRs), VEGFRs, stem cell factor receptor
(c-KIT), Flt-3, colony-stimulating factor receptor type 1, and
the glial cell line-derived neurotrophic factor receptor
(RET).8,9 S is a logical choice as a combination RTK inhibitor
with B. Data indicate that S has a higher affinity for PDGFR
and Flt-3 than for VEGFR-2 and -3, thereby preferentially
targeting angiogenesis pathways that are not targeted by
B.8–10 S is Food and Drug Administration approved for
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treatment of gastrointestinal (GI) stromal tumors, in patients
whose disease has progressed or who are unable to tolerate
imatinib, and for treatment of advanced renal cell carcinoma
(RCC).10 S at 50 mg/d (4 weeks on and 2 weeks off) has been
evaluated in a phase II trial of NSCLC refractory to chemo-
therapy.11 Six patients in this study achieved a partial re-
sponse (9.5%), and 12 had stable disease (19%), with median
progression-free survival (PFS) and overall survival (OS) of
11.3 weeks and 23.9 weeks, respectively.
Data from preclinical models, including animal studies,
have suggested that the addition of S to PCB (PCB  S)
could result in greater (additive) inhibition of VEGF signal-
ing pathways.12 To date, combining more than a single-
targeted therapy (i.e., B) with a platinum doublet (PC) to
form a “quartet” has not been evaluated in NSCLC.
An on-going phase I/II investigator-sponsored trial for
patients with RCC was evaluating the effect of combining
B  S, in doses escalating from 25 to 50 mg/d.13 The
potential tolerability of this antiangiogenic combination ther-
apy was unknown, including potential for overlapping toxic-
ities.4,10 Early results from this study showed that a dose of 25
mg/d resulted in partial response in a subset of patients, with
no new safety signals reported. Based on these early results in
RCC, the Study Assessing the Blockade of both VEGF
Receptor and ligand to enhance Efficacy in Lung (SABRE-L)
study was initiated for patients with advanced NSCLC, to make
a preliminary evaluation of the safety and efficacy of PCB  S
compared with standard PCB for first-line treatment. The pri-
mary objective of SABRE-L was assessment of PFS. Secondary
objectives were the assessment of safety, objective response
rates, duration of objective response, and OS.
PATIENTS AND METHODS
Patient Eligibility
The SABRE-L study enrolled patients with advanced,
histologically or cytologically confirmed, nonsquamous NSCLC
(stage IIIb with malignant pleural or pericardial effusion, stage
IV, or recurrent; mixed tumors confirmed by predominant cell
histology), including patients with measurable or nonmeasur-
able disease. Patients with squamous cell carcinoma were
eligible provided that disease was extrathoracic or intratho-
racic consisting of peripheral lesions only. Patients with
treated brain metastases, and no evidence of progression or
hemorrhage after treatment, were also eligible. All eligible
patients had Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 0 or 1, were 18 years, and
provided signed informed consent.
Exclusion criteria included prior systemic chemother-
apy for metastatic disease; active malignancy other than lung
cancer; prior treatment with anti-VEGF agents or agents
targeting similar RTK pathways as S; adjuvant chemotherapy
or prior combined modality neoadjuvant therapy within 6
months before study enrollment; known central nervous sys-
tem disease except for treated brain metastases; inadequately
controlled hypertension; other known B- or S-specific exclu-
sion criteria; and standard general medical exclusion criteria.
Excluded concomitant medications included antineo-
plastic agents other than PC, dexamethasone (except as pre-
medication for chemotherapy), anticonvulsants, radiotherapy,
epidermal growth factor receptor inhibitors, other angiogen-
esis inhibitors, and CYP3A4 inhibitors or inducers. A proto-
col amendment permitted use of prophylactic and full-dose
therapeutic anticoagulants, as appropriate. Other concomitant
FIGURE 1. Study schema. PCB, paclitaxel/carboplatin  bevacizumab; S, sunitinib.
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medications were permitted, including epoetin (except pro-
phylactically during the first administration cycle), granulo-
cyte colony-stimulating factor (only for neutropenia if not
improved after dose reductions of study drug in the preceding
cycle), nonsteroidal anti-inflammatory drugs, oral contracep-
tives, and hormone replacement therapy, provided at inves-
tigators’ discretion.
Study Design
SABRE-L was a dose-escalation, randomized, con-
trolled, open-label, multicenter trial. Three enrollment stages
were planned (Figure 1), the first being a two-cohort stage,
PCB or PCB  S 25 mg/d, to assess tolerability of PCB  S
at this dose in patients with NSCLC. After safety data from
3 patients in each treatment arm, with 6 weeks follow up
(two cycles), were available, overall tolerability in the PCB S
arm was evaluated. If the data suggested that the PCB  S
combination was well tolerated, then the study was to con-
tinue enrollment. Based on continued tolerability, the study
design included a second three-cohort stage, including PCB,
PCB  S 25 mg/d, and PCB  S 37.5 mg/d. The third study
stage was to include two cohorts, PCB and PCB  S at 25 or
37.5 mg/d, based on the highest tolerable dose, until full
enrollment. The randomization scheme ensured similar pro-
portions of patients within each cohort had ECOG PS 0 or 1.
Written documentation of institutional review board review
and approval of study protocol were obtained.
Patients were to receive the assigned treatment until dis-
ease progression, unacceptable toxicity, or withdrawal of con-
sent, for a maximum of 12 months. Patients who discontinued
FIGURE 2. Consort flowchart. PCB, paclitaxel/carboplatin  bevacizumab; S, sunitinib.
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either B or S were considered off study treatment but could
continue treatment with the other components of the assigned
treatment regimen, at investigators’ discretion. Discontinued
patients and patients who completed study treatment were fol-
lowed up for survival every 3 months until death, withdrawal of
consent, loss to follow-up, or study termination. No crossover to
S treatment was planned for the PCB cohort at any time.
Dosing
B (15 mg/kg) was administered by intravenous infusion
every 3 weeks. C (area under the curve  6) and P (200
mg/m2) were administered by intravenous infusion every 3
weeks for four cycles. S (25 mg/d) was administered orally
for 2 weeks followed by 1 week of rest (“intermittent admin-
istration”). A treatment cycle was defined as 3 weeks.
Safety Monitoring and Treatment
Discontinuation
Throughout the trial, safety was closely monitored
using a real-time safety monitoring database. An independent
scientific advisory board, consisting of external medical ex-
perts, was established to perform a comprehensive evaluation
of safety signals on a regular basis. Patients were followed up
for serious adverse events until 60 days after discontinuation
of B (if applicable).
Patients were required to discontinue from B and S if
they experienced grade 4 hypertension or grade 3 uncon-
trolled hypertension, any grade pulmonary hemorrhage, grade
2 central nervous system hemorrhage, symptomatic grade 4
venous thrombosis, any grade arterial thromboembolic event,
grade 4 left ventricular systolic dysfunction, nephrotic syn-
drome, any grade GI perforation, grade2 bowel obstruction
not fully recovered despite medical or surgical intervention,
wound dehiscence requiring medical/surgical intervention,
and any grade reversible posterior leukoencephalopathy syn-
drome. Patients experiencing the following adverse events,
which did not resolve within 21 days or recurred following S
resumption, were also required to discontinue S: grade 3
left ventricular systolic function, grade 3 fatigue/asthenia,
hand-foot disease, or stomatitis. No dose reductions of B
were permitted in this study; reduction of S to 12.5 mg/d was
permitted for patients who experienced certain events.
Efficacy Evaluation
All patients were evaluated for tumor response at baseline
and every 6 weeks while on study treatment, until disease
progression, start of subsequent antineoplastic therapy, or death.
Tumor response was assessed by investigators using RECIST.
Patients were followed up for survival until the close of the study.
Statistics
The planned sample size (100–130 patients) was se-
lected to permit randomization of at least 45 patients to each
treatment cohort and to provide adequate precision for the
hazard ratio estimates of PFS (the primary efficacy outcome).
PFS was defined as time from randomization to disease
progression or death on study (within 30 days of the last study
treatment), whichever occurred first. Kaplan-Meier methods
were used to characterize the PFS distribution for each
treatment cohort, including estimation of median PFS.
OS was defined as the time from randomization to
death due to any cause. As with the PFS analysis, survival
was analyzed using Kaplan-Meier methods, and the median
survival was estimated for both treatment arms.
Responses were analyzed using a tabulation of best
overall response for patients who had at least one scan at
baseline and postbaseline. Per RECIST, follow-up scans were
required to confirm any partial or complete responses.
Summaries of safety, demographics, and baseline char-
acteristics are provided descriptively by number and percent-
age (n, %), and median and range.
RESULTS
Patient Characteristics
Between March 2007 and January 2008, 56 patients
enrolled in the SABRE-L study and were randomized to
receive PCB (26 patients) or PCB  S (30 patients) (Figure
2). In this first phase of enrollment, patients in the PCB  S
cohort received 25 mg/d S. The trial was stopped due to
tolerability issues in the first enrollment phase on January 18,
TABLE 1. Summary of Demographic and Baseline
Characteristics
Characteristics
PCB  S
(n  30)
PCB
(n  26)
Age (yr)
Median (range) 65 (45–80) 66 (46–80)
Sex, n (%)
Male 16 (53) 14 (54)
Female 14 (47) 12 (46)
Race, n (%)
White 29 (97) 23 (89)
Black 0 (0) 1 (4)
Othera 1 (3) 2 (8)
ECOG performance status, n (%)
0 15 (50) 10 (39)
1 15 (50) 16 (62)
Predominant histology, n (%)
Large cell carcinoma 2 (7) 1 (4)
Squamous cell carcinoma 1 (3) 1 (4)
Adenocarcinoma 25 (83) 22 (85)
Other 2 (7) 2 (8)
Stage, n (%)
IIIb 3 (10) 4 (15)
IV 24 (80) 21 (81)
Recurrent 3 (10) 1 (4)
Most common disease sites, n (%)b
Lung 23 (77) 20 (77)
Mediastinum 6 (20) 7 (27)
Pleural effusion 5 (17) 7 (27)
Liver 5 (17) 10 (39)
Bone 15 (50) 11 (42)
a Other includes Asian, Native Hawaiian and Pacific islander, American Indian, or
Alaska Native.
b Disease site categories are not mutually exclusive.
PCB, paclitaxel/carboplatin  bevacizumab; S, sunitinib; ECOG, Eastern Cooper-
ative Oncology Group.
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2008. The second and third enrollment phases never com-
menced, and the S dose was never escalated to 37.5 mg. Results
reported in this article are based on patient enrollment in the first
phase.
Baseline demographics and characteristics among ran-
domized patients in both cohorts were comparable (Table 1).
All patients were 45 years of age, ethnicity was predomi-
nantly white, and similar numbers of patients had ECOG PS
0 or 1. The predominant histology was adenocarcinoma, and
one patient in each cohort (PCB and PCB  S) had NSCLC
of squamous histology. The majority of patients had stage IV
disease at study entry. The most common disease site in both
cohorts was lung, with lower numbers of patients experienc-
ing involvement in bone, liver, mediastinum, and pleural
effusion. A greater proportion of patients in the PCB cohort
(39%), compared with the PCB  S cohort (17%), entered
the study with disease in the liver.
Treatment Duration
Because of a high rate of discontinuation in the PCB S
cohort (see below), estimated treatment duration was sig-
nificantly lower than in the PCB cohort: median treatment
duration for PCB S was 6 weeks (range1–31), compared
with median treatment duration for PCB of 10 weeks (range
1–33). Patients in the PCB cohort received a median of
four doses PCB, compared with two doses PCB in the
PCB  S cohort.
Safety
All but one of the enrolled patients (in the PCB  S
cohort) received at least one dose of study treatment and
were therefore safety evaluable: 26 patients received PCB
and 29 patients received PCB  S. Adverse events occur-
ring at 5% incidence (i.e., in more than one patient) are
shown in Table 2.
There was an unexpectedly high incidence of  grade
3 laboratory hematologic adverse events in this study, partic-
ularly in the PCB  S cohort. Grades 3 and 4 leukopenia
occurred in three patients (11.5%) in the PCB cohort and
eight patients (27.6%) in the PCB  S cohort; grades 3 and
4 neutropenia occurred in 13 patients (50.0%) in the PCB
cohort and 19 patients (65.5%) in the PCB  S cohort; and
two patients (7.7%) in the PCB cohort and four patients
(13.8%) in the PCB  S cohort experienced febrile neutro-
penia. Grades 3 to 4 thrombocytopenia occurred in five
patients (19.2%) in the PCB cohort and 11 patients (37.9%)
in the PCB  S cohort.
Adverse events commonly attributed to S were observed
in this study, including fatigue, nausea, diarrhea, stomatitis,
hypertension, thromboembolic events, hemorrhagic events, rash,
and laboratory abnormalities. Observed adverse events associ-
ated with B included hypertension, hemorrhagic events, throm-
boembolic events, left ventricular systolic dysfunction, and lab-
oratory abnormalities. Other toxicities known to be associated
with B and/or S (e.g., GI perforation and reversible posterior
leukoencephalopathy) were not observed in this study.
A total of 18 deaths occurred during the study; 13 were
due to disease progression; five deaths were due to grade 5
adverse events, three (11.5%) in the PCB cohort (pulmonary
hemorrhage, renal failure, and cardiac arrest), and two (6.7%)
in the PCB S cohort (collapsed lung and cardiac arrest). Of
TABLE 2. Grade  3 Adverse Eventsa Occurring at 5% Total Incidence
AE Preferred Term
n (%)
PCB  S (N  29)b PCB (N  26)b
Total Grade 3 Grade 4 Grade 5 Total Grade 3 Grade 4 Grade 5
Neutropenia 19 (65.5) 5 (17.2) 14 (48.3) 0 13 (50.0) 4 (15.4) 9 (34.6) 0
Thrombocytopenia 11 (37.9) 5 (17.2) 6 (20.7) 0 5 (19.2) 4 (15.4) 1 (3.8) 0
Leukopenia 8 (27.6) 5 (17.2) 3 (10.3) 0 3 (11.5) 2 (7.7) 1 (3.8) 0
Febrile neutropenia 4 (13.8) 4 (13.8) 0 0 2 (7.7) 2 (7.7) 0 0
Hypertension (de novo) 3 (10.3) 3 (10.3) 0 0 1 (3.8) 1 (3.8) 0 0
Dehydration 2 (6.9) 2 (6.9) 0 0 1 (3.8) 1 (3.8) 0 0
Dyspnea 2 (6.9) 2 (6.9) 0 0 2 (7.7) 2 (7.7) 0 0
Fatigue 2 (6.9) 1 (3.4) 1 (3.4) 0 3 (11.5) 2 (7.7) 1 (3.8) 0
Pulmonary embolism 2 (6.9) 0 2 (6.9) 0 1 (3.8) 1 (3.8) 0 0
Rash 2 (6.9) 2 (6.9) 0 0 0 0 0 0
Cardiac arrest 1 (3.4) 0 0 1 (3.4) 1 (3.8) 0 0 1 (3.8)
Diarrhea 1 (3.4) 1 (3.4) 0 0 1 (3.8) 1 (3.8) 0 0
Pain 1 (3.4) 1 (3.4) 0 0 2 (7.7) 2 (7.7) 0 0
Hyperglycemia 0 0 0 0 2 (7.7) 1 (3.8) 1 (3.8) 0
Hypersensitivity 0 0 0 0 2 (7.7) 2 (7.7) 0 0
Hyponatremia 0 0 0 0 2 (7.7) 2 (7.7) 0 0
Pleural effusion 0 0 0 0 2 (7.7) 2 (7.7) 0 0
Pneumonia 0 0 0 0 2 (7.7) 2 (7.7) 0 0
a For patients experiencing more than one event of the same type, the highest grade of event is reported.
b Patients who received at least one dose of bevacizumab or sunitinib.
PCB, paclitaxel/carboplatin  bevacizumab; S, sunitinib; AE, adverse event.
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the five deaths that were due to grade 5 adverse events, three
were assessed by the investigator to be related to or possibly
related to study treatment: pulmonary hemorrhage (B, C, and P),
collapsed lung (B and S), and cardiac arrest (P). Disease under
study and concurrent illness were the additional suspected
causes for four of the five adverse events resulting in death.
Adverse Events Leading to Dose Modifications
and Treatment Discontinuation
Patients in the PCB  S cohort experienced more B
interruptions (38% versus 19%) and discontinuation (52% ver-
sus 35%) due to adverse events than patients in the PCB cohort
(Table 3). Of the patients in the PCB  S cohort, the majority
(83%) experienced adverse events that resulted in an S dose
change or discontinuation (Table 3). Ten patients (35%) in the
PCB  S cohort had an S dose reduction to 12.5 mg, and 17
patients (59%) permanently discontinued S due to an adverse
event (Table 3). Of the 11 patients in the PCB  S cohort who
had interruptions in B administration, three (27%) also expe-
rienced concomitant interruptions in administration of both C
and P. Of the five patients in the PCB cohort who had
interruptions in B administration, three (60%) had concomi-
tant interruptions in administration of both C and P. The
majority of events resulting in interruptions were grades 3 to
4 thrombocytopenia, neutropenia, febrile neutropenia, ane-
mia, and leukopenia. The most common adverse events that
led to B discontinuation were thrombocytopenia, neutropenia,
febrile neutropenia, anemia, and leukopenia.
Efficacy Evaluation
PFS and OS data were limited by the small number of
patients who actually enrolled in the study and the short duration
of response and survival follow-up due to early study termina-
tion. Median PFS was 4.5 months (95% confidence interval
[CI]: 4.1, upper limit not estimable) in the PCB cohort and 3.8
months (95% CI: 3.5, 7.3) in the PCB  S cohort. Median OS
for the PCB S cohort was 6.6 months (95% CI: 3.6 months,
upper limit not estimable); median OS for the PCB cohort
was not reached at the time of the analysis.
Analyses pertaining to objective response and duration
of objective response were not conducted due to limited
follow-up of response data. Among evaluable patients (i.e.,
those with an available baseline and 1 postbaseline scan),
there were 2 (8%) confirmed partial responses among the 25
patients in the PCB  S cohort, and 5 (26%) among the 19
patients in the PCB cohort (Table 4).
DISCUSSION
The rationale for combining B and S was to target mul-
tiple VEGF-related pathways to override primary or acquired
nonresponsiveness to therapy with B alone. Preclinical models
suggested that tumor targeting with the combination of B and S
could have an additive effect on efficacy.12 However, the addi-
tion of S to PCB in the SABRE-L study was not well tolerated
at the 25 mg dose, preventing escalation to the 37.5 mg S dose,
and resulting in a high rate of dose reductions and discontinua-
tions. This in turn compromised the administration of the stan-
dard treatment of PCB in this disease setting.
The combination of B and S may have increased the
incidence of adverse events, particularly myelosuppressive
events, known to occur as a consequence of chemotherapy-
related toxicities. The main safety issue to emerge from this
study was the unexpectedly high incidence of laboratory
hematologic deficiencies (grades 3–4 thrombocytopenia, leu-
kopenia including neutropenia, febrile neutropenia, and
thrombocytopenia) in patients who received PCB  S. Many
of these events led to dose reduction of S or discontinuation.
Although preclinical models had shown that combination
targeting of VEGF/RTK inhibitors increased the efficacy of
either drug,12 the results of this study suggest there are also
detrimental effects on hematopoiesis and thrombopoiesis. It is
known that de novo production of leukocytes, granulocytes, and
megakaryocyte-derived platelets depends on complex pathways
that include c-kit, Flt3, VEGFRs, and PDGFRs.14
There were five grade 5 adverse events, including three
in the PCB arm. The sample size in this study was small and
this incidence does not reflect what has been seen in trials or
studies of BV in NSCLC conducted to date including E45995
and B017704.15 Overall, no new safety signals were observed
with the addition of 25 mg S to PCB, when compared with the
known adverse event profiles for B or S. However, the additive
effect of combining S with PCB resulted in increased levels of
combined class-specific known toxicities that were deemed
unacceptable and that ultimately resulted in early termination of
the study by the sponsor.
TABLE 3. Adverse Events Resulting in Changes to Drug
Administration
PCB  S
(N  29)a
PCB
(N  26)a
Adverse events resulting in changes
to B administration, n (%)
21 (72) 13 (50)
Drug permanently discontinued 15 (52) 9 (35)
Drug treatment interrupted 11 (38) 5 (19)
Adverse events resulting in changes
to S administration, n (%)
24 (83) NA
Drug permanently discontinued 17 (59) NA
Dose decreased 10 (35) NA
Drug treatment interrupted 15 (52) NA
a Patients who received at least one dose of bevacizumab or sunitinib.
B, bevacizumab; S, sunitinib; NA, not applicable; PCB, paclitaxel/carboplatin 
bevacizumab.
TABLE 4. Best Overall Response
Best Overall Response
PCB  S
(n  25)a
PCB
(n  19)a
Complete response,b n (%) 0 0
Partial response,b n (%) 2 (8) 5 (26)
Stable disease, n (%) 20 (80) 13 (68)
Progressive disease, n (%) 2 (8) 1 (5)
Missing, n (%) 1 (4.0) 0
a Randomized patients with baseline scan and at least one postbaseline scan.
b Responses were confirmed per RECIST after a subsequent visit 4 wk later.
PCB, paclitaxel/carboplatin  bevacizumab; S, sunitinib.
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Efficacy conclusions based on PFS and OS are limited by
the small sample size and short follow-up of response and
survival data. Median PFS was 4.5 months (95% CI: 4.1, upper
limit unevaluable) for the PCB cohort and 3.8 months (95% CI:
3.5, 7.3) for the PCB S cohort. Patients in the PCB S cohort
received less treatment (median of 6 weeks) than patients receiving
PCB alone (median of 10weeks). In summary, the PCBS cohort
had a lower median time on treatment, a higher incidence of
unacceptable toxicities, and a lower median PFS than the PCB
cohort, resulting in an unfavorable risk/benefit profile for the PCB
 S cohort in this disease setting.
The combination of B and S has also been assessed in
two trials for RCC12,13 and in a trial for metastatic breast
cancer.16 In the setting of RCC, a new safety signal, microan-
giopathic hemolytic anemia, emerged in both renal trials: a
dose escalation trial for S  B,12 and the SABRE-R trial of
S  placebo (nine patients) versus S  B (seven patients).14
Severe hypertension was also observed in both RCC trials.
The SABRE-B trial for previously untreated metastatic breast
cancer was a phase II, randomized, controlled trial of B and
P  S16; this trial was also closed prematurely (median of
11.6-week treatment duration) due to toxicity associated with
the B  P  S regimen (23 patients), when compared with
B  P alone (23 patients). Toxicities in SABRE-B consisted
predominantly of neutropenia and other hematologic defi-
ciencies, GI toxicity, and fatigue. To date, the combination of
B and S has not been associated with microangiopathic
hemolytic anemia in any setting except RCC.
SABRE-L was a well-conducted study with rigorous
monitoring and real-time safety reporting. Sites with vast
experience conducting clinical trials of novel biologic agents
were selected. Despite this, the addition of PCB to S at
schedules and doses tested proved to be intolerable and led to
a decision by the sponsor to terminate the study. Although the
decision to try and build on the efficacy of PCB by adding an
RTK inhibitor was scientifically based, it cannot be assumed
that additive toxicities will be minimal when adding newer
agents to existing combinations, as evidenced by the early
termination of this study due to unacceptable toxicities.
It is unknown whether the unacceptable safety profile
for PCB  S observed under these study conditions would
also be observed for combination of PCB with a different
RTK inhibitor. Results from recent cancer trials, including
two trials for NSCLC in which RTK inhibitors (sorafenib and
cediranib) were added to PC,17,18 have suggested that suc-
cessful combination of chemotherapy with RTK inhibitors
may be impeded by the substantial toxicities encountered or
achievement of little or no clinical benefit.19,20
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